

Contents

Preface — v

List of contributing authors — vii

1 Angiotensin converting enzyme — 1

Joe M. El-Khoury, Edmunds Reineks and Sihe Wang

- 1.1 Case studies — 1
 - 1.1.1 Patient A — 1
 - 1.1.2 Patient B — 1
 - 1.1.3 Patient C — 2
- 1.2 Biochemistry and physiology — 3
 - 1.2.1 Physiological function — 3
 - 1.2.2 Biochemistry and molecular forms — 3
 - 1.2.3 Tissue sources — 5
 - 1.2.4 Reference ranges — 5
- 1.3 Chemical pathology — 7
 - 1.3.1 ACE in sarcoidosis — 7
- 1.4 Analysis — 9
 - 1.4.1 Specimen — 9
 - 1.4.2 Spectrophotometric methods — 10
 - 1.4.3 High-performance liquid chromatography — 10
 - 1.4.4 Fluorometric methods — 11
 - 1.4.5 Radioassays — 11
 - 1.4.6 Other methods — 11
 - 1.4.7 Inhibitors of ACE — 12
- 1.5 Questions and answers — 12
 - References — 13

2 Acetylcholinesterase and butyrylcholinesterase — 19

Peter L. Platteborze

- 2.1 Case studies — 19
 - 2.1.1 Patient A — 19
 - 2.1.2 Patient B — 20
 - 2.1.3 Patient C — 21
 - 2.1.4 Patient D — 22
 - 2.1.5 Patient E — 22
- 2.2 Biochemistry and physiology of the cholinesterases — 23
 - 2.2.1 Molecular forms — 23
 - 2.2.2 Inheritance of BChE variants — 26
- 2.3 Chemical pathology — 29

- 2.3.1 Pesticide and nerve agent poisoning — 29
- 2.4 Analytical measurements of AChE and BChE — 36
- 2.4.1 Desired specimens — 36
- 2.5 Questions and answers — 38
- References — 40

3 Aldolase — 41

Edmunds Reineks, Joe M. El-Khoury and Sihe Wang

- 3.1 Case studies — 41
- 3.1.1 Patient A — 41
- 3.1.2 Patient B — 42
- 3.1.3 Patient C — 43
- 3.2 Biochemistry and physiology — 43
- 3.2.1 Physiological function — 43
- 3.2.2 Biochemistry and molecular structure — 44
- 3.2.3 Tissue source(s) and expression of ALD — 45
- 3.2.4 Clearance and metabolism of ALD — 45
- 3.2.5 Reference ranges — 46
- 3.3 Chemical pathology — 47
- 3.3.1 Polymyositis/dermatomyositis — 47
- 3.3.2 Duchenne muscular dystrophy — 48
- 3.3.3 Drug-induced myopathy — 48
- 3.3.4 Pathologies in which CK does not reflect the extent of muscle damage — 49
- 3.4 Analysis — 50
- 3.4.1 Specimen — 50
- 3.4.2 Analyte stability — 51
- 3.4.3 Interferences — 51
- 3.4.4 Reference methods — 51
- 3.5 Questions and answers — 52
- References — 53

4 Alkaline phosphatase — 57

Amy E. Schmidt

- 4.1 Case studies — 57
- 4.1.1 Patient A — 57
- 4.1.2 Patient B — 58
- 4.1.3 Patient C — 59
- 4.1.4 Patient D — 60
- 4.1.5 Patient E — 60
- 4.1.6 Patient F — 61

- 4.2 Biochemistry and physiology — 63
 - 4.2.1 Structure — 63
 - 4.2.2 Physiological function of ALP in tissue/blood/other fluids — 66
 - 4.2.3 Tissue sources of ALP — 66
 - 4.2.4 Clearance/metabolism of enzyme — 67
 - 4.2.5 Reference ranges — 67
- 4.3 Chemical pathology — 68
 - 4.3.1 Liver disease — 68
 - 4.3.2 Bone disease — 69
 - 4.3.3 Metastatic cancer — 69
 - 4.3.4 Miscellaneous pancreatic disorders — 69
 - 4.3.5 Cystic fibrosis — 70
 - 4.3.6 Chronic renal failure — 70
 - 4.3.7 Drug therapy — 70
 - 4.3.8 Miscellaneous — 71
- 4.4 Analysis — 71
 - 4.4.1 Technical problems — 71
 - 4.4.2 Reference method — 72
 - 4.4.3 Isoenzyme analysis — 72
- 4.5 Questions and answers — 75
 - Acknowledgements — 75
 - References — 76

5 Aspartate aminotransferase and alanine aminotransferase — 81

Joe M. El-Khoury and Sihe Wang

- 5.1 Case studies — 81
 - 5.1.1 Patient A — 81
 - 5.1.2 Patient B — 82
 - 5.1.3 Patient C — 82
 - 5.1.4 Patient D — 83
 - 5.1.5 Patient E — 84
- 5.2 Biochemistry and physiology — 84
 - 5.2.1 Molecular forms — 84
 - 5.2.2 Biochemical function — 86
 - 5.2.3 Normal physiology — 86
 - 5.2.4 Reference ranges — 88
- 5.3 Chemical pathology — 89
 - 5.3.1 Liver disease — 89
 - 5.3.2 Hemochromatosis — 92
 - 5.3.3 Skeletal muscle disease — 93
 - 5.3.4 Heart disease — 94
 - 5.3.5 Other causes of AST increase — 95

- 5.4 Analysis — 95
 - 5.4.1 Specimens — 95
 - 5.4.2 Reaction used — 95
 - 5.4.3 Interferences — 96
 - 5.4.4 Methods for AST isoenzymes — 97
- 5.5 Questions and answers — 97
- References — 98

- 6 Creatine kinase, isoenzymes, and isoforms — 105**
Alan H.B. Wu
 - 6.1 Case studies — 105
 - 6.1.1 Patient A — 105
 - 6.1.2 Patient B — 106
 - 6.1.3 Patient C — 107
 - 6.1.4 Patient D — 108
 - 6.1.5 Patient E — 109
 - 6.2 Biochemistry and physiology — 110
 - 6.2.1 Molecular forms — 110
 - 6.2.2 CK isoenzymes, atypical forms, and isoforms — 111
 - 6.2.3 Reference range — 114
 - 6.3 Chemical pathology — 114
 - 6.3.1 Heart disease — 114
 - 6.3.2 Skeletal muscle disease — 116
 - 6.3.3 Trauma — 116
 - 6.4 Analytical measurement of total CK and CK-MB — 117
 - 6.5 Questions and answers — 118
 - References — 119

- 7 Gamma-glutamyl transferase — 121**
Sarah M. Brown
 - 7.1 Case studies — 121
 - 7.1.1 Patient A — 121
 - 7.1.2 Patient B — 121
 - 7.1.3 Patient C — 122
 - 7.1.4 Patient D — 123
 - 7.1.5 Patient E — 124
 - 7.2 Biochemistry and physiology — 124
 - 7.2.1 Molecular forms and post-translational modification — 124
 - 7.2.2 Biochemical function — 125
 - 7.2.3 Tissue activities and concentrations — 125
 - 7.2.4 Metabolic clearance — 126
 - 7.2.5 Reference intervals — 126

- 7.3 Chemical pathology — 126
- 7.3.1 Causes of increased or decreased concentrations or activities — 126
- 7.3.2 Diagnostic utility of GGT — 127
- 7.4 Analysis — 131
- 7.4.1 Specimen and stability — 131
- 7.4.2 Preferred method for GGT activity — 131
- 7.5 Questions and answers — 132
- References 132

8 Lactate dehydrogenase — 135

Olajumoke Oladipo and Dennis J. Dietzen

- 9.1 Case studies — 135
- 8.1.1 Patient A — 135
- 8.1.2 Patient B — 136
- 8.1.3 Patient C — 137
- 8.1.4 Patient D — 138
- 8.1.5 Patient E — 139
- 8.2 Biochemistry and physiology — 140
- 8.2.1 Physiological function — 140
- 8.2.2 Tissue sources — 140
- 8.2.3 Reference ranges — 141
- 8.3 Chemical pathology — 141
- 8.3.1 Cardiology — 142
- 8.3.2 Hepatology — 142
- 8.3.3 Hematology — 142
- 8.3.4 Oncology — 143
- 8.3.5 Neurology — 143
- 8.3.6 Macro-LD — 144
- 8.3.7 Genetic deficiencies — 144
- 8.4 Analysis — 144
- 8.4.1 LD isoenzyme determination — 145
- 8.4.2 IFCC reference method — 145
- 8.4.3 Specimen — 146
- 8.5 Questions and answers — 146
- References — 147

9 Pancreatic lipase — 153

Wan-Ming Zhang, Edmunds Reineks, Joe M. El-Khoury and Sihe Wang

- 9.1 Case studies — 153
- 9.1.1 Patient A — 153
- 9.1.2 Patient B — 154

- 9.1.3 Patient C — 155
- 9.1.4 Patient D — 156
- 9.2 Biochemistry and physiology — 157
 - 9.2.1 Molecular forms — 157
 - 9.2.2 Molecular structure and tissue expression — 158
 - 9.2.3 Mechanism of catalysis — 159
 - 9.2.4 Functional regulation — 159
 - 9.2.5 Lipase in serum — 161
 - 9.2.6 Other lipases — 162
 - 9.2.7 Reference range and standardization — 164
- 9.3 Chemical pathology — 164
 - 9.3.1 Acute pancreatitis — 164
 - 9.3.2 Pancreatic cancer — 165
 - 9.3.3 Cystic fibrosis — 166
 - 9.3.4 Diabetic ketoacidosis — 166
 - 9.3.5 Chronic renal failure — 167
 - 9.3.6 Iatrogenic effects — 167
 - 9.3.7 Drug effects — 167
- 9.4 Analysis — 168
 - 9.4.1 Specimen — 168
 - 9.4.2 Methods and instrumentation — 168
- 9.5 Questions and answers — 171
 - References — 172

- 10 Natriuretic peptides — 181**
 - Robert H. Christenson and Hassan M.E. Azzazy
 - 10.1 Case studies — 181
 - 10.1.1 Patient A — 181
 - 10.1.2 Patient B — 182
 - 10.1.3 Patient C — 182
 - 10.1.4 Patient D — 183
 - 10.1.5 Patient E — 184
 - 10.1.6 Patient F — 185
 - 10.2 Biochemistry and physiology of cardiac natriuretic peptides — 185
 - 10.3 Chemical pathology of natriuretic peptides — 186
 - 10.3.1 BNP in diagnosis of symptomatic HF patients — 187
 - 10.3.2 Prognosis and risk stratification of HF patients — 187
 - 10.3.3 BNP and NT-proBNP as prognostic risk markers in acute coronary syndrome patients — 188
 - 10.3.4 Recommendations for use of Biochemical markers in heart failure — 188

- 10.4 Analytical measurements of BNP and NT-proBNP — 188
- 10.4.1 Desired specimens — 188
- 10.4.2 Considerations for measurements of BNP and NT-proBNP — 189
- 10.4.3 Methods for measurements — 190
- 10.5 Questions and answers — 191
- References — 192

Index — 195